The 2019 FASEB Science Research Conference on Lysophospholipid and Related Mediators: From Bench to Clinic, July 28 to August 2, 2019, Lisbon, Portugal.
The 2019 FASEB Science Research Conference on Lysophospholipid and Related Mediators: From Bench to Clinic, July 28 to August 2, 2019, Lisbon, Portugal.
复制标题
2019年FASEB溶血磷脂及相关介质科学研究会议：从实验室到临床，2019年7月28日至8月2日，葡萄牙里斯本。
DOI：
10.1096/fj.201902224
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
McMullen,ColleenA
中科院分区：
文献类型：
--
作者：
Smyth,SusanS;Natarajan,Viswanathan;McMullen,ColleenA
FASEB科学研究会议”溶血磷脂和相关介体：从实验室到临床”会议于2019年7月28日至8月2日在葡萄牙里斯本举行，作为FASEB 2019科学研究会议（SRC）系列的一部分。FASEB会议重点关注与生物活性溶血磷脂及其在健康和疾病中的作用相关的当前和新兴概念，重点关注信号通路的基础生物学以及将工作转化为药物开发和临床实践。在四天半的时间里，55名特邀发言人和2名主旨发言人介绍了新出版的作品，并附有48张海报。鉴于针对其信号通路的临床治疗的可用性和发展，鞘氨醇-1-磷酸（S1 P）和溶血磷脂酸（LPA）是许多会议的重点，但其他新兴的生物活性脂质介质也在几次演讲中被提及。FASEB会议还为年轻和新的研究人员提供了一个平台，让他们与高级首席研究员和教授就职业发展和进步，指导，博士后奖学金和生物制药研究进行一对一的交谈。与会的女科学家举行了一次单独的会议，讨论妇女在促进妇女健康的药物的基础、转化和临床研究和开发中的作用。FASEB科学研究会议系列是在世界各地不同地点举行的30至40个会议的年度计划。这个FASEB会议已经两年一度的事件为20年，填补了一个独特的和具体的需要，在该领域提供了一个论坛，为基础科学家和临床研究人员之间的互动。例如，免疫调节药物芬戈莫德（Gilenya; Novartis，巴塞尔，瑞士）靶向S1 P受体信号传导，现在被美国食品和药物管理局批准用于治疗多发性硬化症，在2001年的FASEB会议上首次报道。今年，与会者听取了GLPG 1690（一种产生LPA的溶血磷脂酶D自分泌运动因子（ATX）的抑制剂）早期临床试验的可喜结果，以及伊萨贝拉3期试验的启动，该试验在1500名特发性肺纤维化（IPF）患者中研究GLPG 1690。一些演讲强调了针对S1 P和LPA代谢酶的新型和新型小分子抑制剂的开发。会议开始时，Jason Cyster博士（美国加州大学弗朗西斯科分校）发表了主题演讲，他是第一位Tager荣誉演讲者，这一称号是在今年的会议上建立的，以表彰Andrew Tager博士对溶血磷脂领域的贡献，特别是他对IPF中LPA信号传导的识别。Cyster的工作已经定义了淋巴细胞在组织和血液之间以S1 P调节的方式运输的基本方面。他的演讲包括对细胞类型特异性S1 P受体的鉴定、淋巴细胞活化抗原CD 69对受体的调节以及香叶基香叶基-L-谷胱甘肽作为Ga 13偶联P2 RY 8受体的新型配体的鉴定的讨论，该受体可抑制B细胞的迁移并调节其生长（1）。随后，脂质研究杂志奖获得者大卫Brindley博士（图1;加拿大阿尔伯塔省埃德蒙顿市阿尔伯塔大学）发表了关于通过乳房脂肪产生ATX调节乳腺癌的主题演讲，并提供了令人信服的证据证明ATX/LPA信号通路是适应不良炎症的调节剂（2）。S1 P和LPA信号的作用
The FASEB Science Research Conference" Lysophospholipid and Related Mediators: From Bench to Clinic" conference was held in Lisbon, Portugal, from July 28 through August 2, 2019 as part of the FASEB 2019 Science Research Conference (SRC) series. The FASEB conference focused on current and emerging concepts related to bioactive lysophospholipids and their roles in health and disease, with emphasis on both the underlying biology of the signaling pathways and translation of work into drug development and clinical practice. Over the course of four and one-half days, 55 invited and 2 keynote speakers presented new and published work, supplemented with 48 posters. Given the availability and development of clinical therapeutics targeting their signaling pathways, sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) were the focus of many of the sessions, but other emerging bioactive lipid mediators were covered in several presentations. The FASEB conference also served as a platform for young and new investigators to chat one-onone with senior principal investigators and professors on career development and advancement, mentoring, postdoctoral fellowships, and research in biopharma. A separate session by the participating women scientists addressed the role of women in basic, translational, and clinical research and development of drugs for women's health. The FASEB Science Research Conference series is an annual program of 30 to 40 conferences, held in different locations around the world. This FASEB conference has been a biennial event for 20 years, filling a unique and specific need in the field by providing a forum for interactions between basic scientists and clinical researchers. As an example, the immunomodulating drug fingolimod (Gilenya; Novartis, Basel, Switzerland), which targets S1P receptor signaling and is now US Food and Drug Administration approved for the treatment of multiple sclerosis, was first reported at this FASEB conference in 2001. This year, attendees heard the promising results of early phase clinical trials of GLPG1690, an inhibitor of the lysophospholipase D autotaxin (ATX) that generates LPA, and the launch of the ISABELA phase 3 trial to study GLPG1690 in 1500 patients with idiopathic pulmonary fibrosis (IPF). Several presentations highlighted development of new and novel small molecule inhibitors targeting enzymes of S1P and LPA metabolism for therapy. The conference began with a keynote presentation by Dr. Jason Cyster (University of California, San Francisco, San Francisco, CA, USA), who was the first Tager Honored Speaker, a designation established at this year's conference as enduring recognition of Dr. Andrew Tager's contributions to the lysophospholipid field, in particular his identification of LPA signaling in IPF. Cyster's work has defined fundamental aspects of lymphocyte trafficking between tissue and blood in a S1P-regulated manner. His presentation included discussion on the identification of cell-type-specific S1P receptors, regulation of the receptors by the lymphocyte activation antigen CD69, and the identification of geranylgeranyl-L-glutathione as a novel ligand for the Ga13-coupled P2RY8 receptor that inhibits the migration and regulates growth of B cells (1). Following this, Dr. David Brindley (Fig. 1; University of Alberta, Edmonton, Alberta, Canada), recipient of theJournal of Lipid Research award, gave a keynote address on regulation of breast cancer by mammary adipose production of ATX and provided compelling evidence that the ATX/LPA signaling pathway is a regulator of maladaptive inflammation (2). The roles of S1P and LPA signaling …